ASOs have emerged as a promising RNA‐targeting strategy for neurological diseases, represented by the recent US FDA approval of tofersen, an ASO designed to reduce SOD1 mRNA in ALS patients carrying SOD1 mutations. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.